NeuBase Therapeutics, Inc. (NBSE) Research

Operating as a pre-clinical biopharmaceutical company, NeuBase Therapeutics, Inc. is dedicated to pioneering therapeutic solutions for rare genetic disorders and various cancers stemming from aberrant genes. At the core of its approach is the proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform. This technology is being utilized to target ailments such as Huntington's disease (HD) and myotonic dystrophy, in addition to a broader spectrum of genetic conditions and applications within oncology. The company's leading therapeutic candidates encompass NT0100, a PATrOL-powered anti-gene therapy for Huntington's disease; NT0200, another PATrOL-enabled anti-gene solution for myotonic dystrophy type 1; and NT0300, a PATrOL-based treatment specifically engineered to address the mutated KRAS gene. NeuBase Therapeutics, Inc. maintains its headquarters in Pittsburgh, Pennsylvania.

Market snapshot

Symbol
NBSE
Price
$0.38
Day change
-1.56%
Market cap
$1.4M
P/E ratio
-0.02x
52-week range
0.36-4.44
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • ASLAN Pharmaceuticals Limited (ASLN)
  • CohBar, Inc. (CWBR)
  • Altamira Therapeutics Ltd. (CYTO)
  • Impel Pharmaceuticals Inc. (IMPL)
  • 9 Meters Biopharma, Inc. (NMTRQ)
  • OncoSec Medical Incorporated (ONCSQ)
  • Oncternal Therapeutics, Inc. (ONCT)
  • Cassava Sciences, Inc. Warrant (SAVAW)

Recent insider activity

  • Symetryx Corp — trade (0 shares) on 2022-12-31
  • Symetryx Corp — S-Sale (129108 shares) on 2023-09-14
  • Symetryx Corp — S-Sale (103337 shares) on 2023-09-15
  • Symetryx Corp — S-Sale (50000 shares) on 2023-09-18
  • Symetryx Corp — trade (0 shares) on 2023-08-23

Open NeuBase Therapeutics, Inc. (NBSE) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.